(Q40207325)

18 September 2017

title

TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group (English)

1 reference

Adaptive radiation therapy

18 September 2017

main subject

0 references

author

Deborah Watkins-Bruner

8

object named as

Deborah Watkins-Bruner

1 reference

18 September 2017

9

Adam S Garden

1 reference

18 September 2017

10

K Kian Ang

1 reference

18 September 2017

Andy Trotti

1

1 reference

18 September 2017

Thomas F Pajak

2

1 reference

18 September 2017

Clement K Gwede

3

1 reference

18 September 2017

Rebecca Paulus

4

1 reference

18 September 2017

Jay Cooper

5

1 reference

18 September 2017

Arlene Forastiere

6

1 reference

18 September 2017

John A Ridge

7

1 reference

18 September 2017

Wally Curran

11

1 reference

18 September 2017

publication date

1 July 2007

1 reference

Lancet Oncology Commission

18 September 2017

published in

1 reference

18 September 2017

volume

8

1 reference

18 September 2017

issue

7

1 reference

18 September 2017

page(s)

613-624

1 reference

Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Variability in the assessment of adverse events in a multicenter clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

The Need for Adverse Effects Reporting Standards in Oncology Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Toxicity in head and neck cancer: a review of trends and issues

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Symptom clusters and quality of life in survivors of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Genetic predictors of adverse radiotherapy effects: the Gene-PARE project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

Adverse events: the more you search, the more you find

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970144-4

7 January 2021

10.1016/S1470-2045(07)70144-4

Identifiers

DOI

1 reference

18 September 2017

1 reference